retatrutide dosing schedule clinical trial VisualAbstract: reduces body weight by 17.5% in patients with obesity Retatrutide Dosage: a Guide -
Description
This makes Retatrutide relevant to laboratory studies involving receptor pathway comparison, metabolic signalling, glucose response models, energy balance research, appetite-related pathway modelling and cardiometabolic research frameworks
But your body won't cooperate
Developed by Eli Lilly, retatrutide is a triple hormone receptor agonist (GLP-1, GIP and glucagon)
However, more studies are needed for future studies
2013;36(suppl 2):S245-S252
